This Is MS Multiple Sclerosis Community: Knowledge & Support

Apparently in the US and most of Europe, Sanofi are withdrawing the unlicensed use of Campath for MS treatment ie use outside of a recognised trial. Drs. will only be able to get it for named cancer patients. I think this starts in the US in November. This is in preparation for it to be licensed under Lemtrada once the EMA and FDA have looked at it.

I had a third dose of alamtuzumab a couple months ago. I took the acyclovir as instructed and all was good but I took my triplets for a well visit and they got the chicken pox booster. I didn't think about it because I've had chicken pox. I forgot about the possibility of getting shingles and now I have them. Please keep it in mind when you get you doses.

Genzyme, a Sanofi company , today announced that the company has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval of Lemtrada(TM) (alemtuzumab) for treatment of relapsing multiple sclerosis (RMS). Genzyme is developing Lemtrada in MS in collaboration with Bayer HealthCare.

Genzyme's clinical development program for Lemtrada included two Phase III studies in which ...

Lemtrada (alemtuzumab) improved disability scores in MS patients over Rebif



Genzyme, a Sanofi company , reports today additional data from the Phase III CARE-MS II trial. Accumulation of disability was significantly slowed in patients with multiple sclerosis (MS) who were treated with alemtuzumab versus Rebif(R) (high dose subcutaneous interferon beta-1a), as measured by the Expanded Disability Status Scale (EDSS), a standard assessment of physical disability progression.

In addition, significant improvement in disability scores was ...

Alemtuzumab more effective than interferon β-1a at 5-year follow-up



Summary: The authors present 5-year follow-up data from the CAMMS223 study, reporting on the long-term safety and efficacy of alemtuzumab treatment compared with interferon β-1a in early, active relapsing-remitting multiple sclerosis (RRMS). Over 5 years, alemtuzumab lowered the risk of sustained accumulation of disability by 72%. The annualised relapse rate over the 5 years was 0.11 for alemtuzumab and 0.35 for IFNβ-1a.

Most commonly occurring ...

Genzyme, a Sanofi company , reports today that the Phase lll CARE-MS ll trial met both of its co-primary endpoints.

Relapse rate and sustained accumulation (worsening) of disability (SAD) were significantly reduced in multiple sclerosis patients receiving alemtuzumab (Lemtrada(TM)) as compared with Rebif(R) (44 mcg subcutaneous interferon beta-1a).

Results for both of these co-primary endpoints were highly statistically significant. CARE-MS II is the randomized Phase III clinical trial comparing the investigational drug alemtuzumab to ...

The first drug to show signs of not just halting multiple sclerosis (MS), but actually reversing the nerve damage caused by the condition, has taken a significant step towards clinical approval.

The results of a phase III trial, presented on 22 October at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis, in Amsterdam, found that 78% of patients treated with the monoclonal antibody alemtuzumab ...

New data from a late-stage trial showed that 78 percent of patients treated with Lemtrada remained relapse-free for two years, compared with 59 percent using Rebif, an older multiple sclerosis drug sold by Germany's Merck.

Lemtrada is a key experimental product at Sanofi's Genzyme unit. The fortunes of the drug are closely watched by holders of Genzyme Contingent Value Rights certificates issued to shareholders as part of the U.S. company's takeover deal.

CVRs represent ...

Summary: Alemtuzumab is a monoclonal antibody, which is a candidate treatment for MS. One of the potential side effects of this medication was the development of autoimmune disease.

In this study the authors prospectively analyse both clinical and serological data of patients with MS treated with alemtuzumab. It was found that autoimmune disease developed in 22.2% of those treated with a range of different systems affected, with thyroid autoimmune disease being seen most commonly ...

Dear all..... I want to use campath in UK, but i don’t know from where to start, can any buddy ( who has experience with this treatment) tell me , what is the best place or clinic which can provide this treatment?

thanks